AnaptysBio (NASDAQ:ANAB - Free Report) had its target price cut by JPMorgan Chase & Co. from $66.00 to $36.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company's stock.
ANAB has been the subject of several other research reports. UBS Group raised their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Wells Fargo & Company cut their target price on AnaptysBio from $56.00 to $40.00 and set an "overweight" rating on the stock in a research note on Thursday, December 12th. BTIG Research lowered AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday, December 2nd. Truist Financial dropped their price objective on AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a report on Wednesday. Finally, Guggenheim reduced their target price on AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, December 12th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $41.45.
View Our Latest Stock Analysis on ANAB
AnaptysBio Trading Down 2.2 %
Shares of NASDAQ:ANAB traded down $0.34 during trading on Thursday, reaching $15.00. The company's stock had a trading volume of 357,950 shares, compared to its average volume of 384,341. The stock has a market capitalization of $456.44 million, a PE ratio of -2.47 and a beta of -0.11. AnaptysBio has a 12 month low of $14.20 and a 12 month high of $41.31. The firm's 50 day simple moving average is $24.59 and its two-hundred day simple moving average is $29.31.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million during the quarter, compared to analysts' expectations of $7.92 million. Research analysts anticipate that AnaptysBio will post -6.02 EPS for the current fiscal year.
Insider Activity
In related news, insider Paul F. Lizzul sold 1,500 shares of the company's stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This represents a 8.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 33.70% of the company's stock.
Hedge Funds Weigh In On AnaptysBio
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its position in shares of AnaptysBio by 117.4% in the 3rd quarter. Barclays PLC now owns 44,300 shares of the biotechnology company's stock worth $1,486,000 after buying an additional 23,926 shares during the last quarter. Geode Capital Management LLC grew its holdings in AnaptysBio by 3.0% in the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company's stock worth $15,594,000 after purchasing an additional 13,336 shares during the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of AnaptysBio by 2.0% during the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company's stock worth $74,008,000 after purchasing an additional 43,598 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of AnaptysBio by 49.1% during the 3rd quarter. XTX Topco Ltd now owns 20,286 shares of the biotechnology company's stock valued at $680,000 after purchasing an additional 6,683 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of AnaptysBio by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 65,939 shares of the biotechnology company's stock worth $2,209,000 after purchasing an additional 3,048 shares in the last quarter.
About AnaptysBio
(
Get Free Report)
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Featured Stories
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.